earningsconfidence high
Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026
Atea Pharmaceuticals, Inc.
2026-Q1 EPS
reported -$0.57
vs consensus -$0.60
▲ beat
(+5.3%)
- Net loss $45.4M vs $34.3M YoY; R&D spend rose to $41.1M on HCV Phase 3 and HEV preclinical.
- Cash, equivalents & marketable securities $256.0M at March 31, 2026, down from $301.8M at Dec 2025.
- C-BEYOND HCV Phase 3 (North America) enrollment completed; topline results expected mid-2026.
- C-FORWARD HCV Phase 3 (ex-North America) enrollment on track to complete mid-2026; topline around year-end 2026.
- HEV program: AT-587 selected as lead; in vitro data 30-150x more potent than sofosbuvir/ribavirin; Phase 1 initiation planned mid-2026.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.